Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer.
The widespread availability of luteinizing hormone-releasing hormone analogues has renewed interest in androgen-deprivation therapy (ADT) before radical prostatectomy. Neoadjuvant ADT in patients with clinically localized tumors has resulted in decreased margin-positive rates and increased rates of organ-confined disease. Unfortunately, the pathological effects of ADT in patients with locally advanced (cT3) prostate cancer have been less marked. This article reviews our experience with neoadjuvant hormonal therapy in patients with clinical stage T3 prostate cancer. In a case-control study of cT3 patients undergoing radical retropubic prostatectomy between 1985 and 1992, 72 patients receiving preoperative ADT were compared with a matched group of 144 untreated patients in terms of pathological outcome and long-term disease-free survival. A local downstaging effect in hormonally treated patients was suggested by lower rates of extracapsular extension, but only 31% had organ-confined disease. Hormonally treated patients showed no benefit in survival or disease progression compared with patients who did not receive this therapy. Although preoperative ADT may decrease the incidence of extracapsular extension in clinical stage T3 prostate cancer, our data suggest that it has no significant effect on survival or disease progression in patients with locally advanced disease.
Amling
C L
CL
Department of Urology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
Blute
M L
ML
Bergstralh
E J
EJ
Slezak
J M
JM
Martin
S K
SK
Zincke
H
H
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D016022:Case-Control Studies; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011300:Preoperative Care; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000601:surgery / Q000628:therapy*; D012189:Retrospective Studies
D000726:Androgen Antagonists